Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.
Saved in:
| Title: | Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling. |
|---|---|
| Authors: | El Zarif T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Yale School of Medicine, New Haven, Connecticut., Meador CB; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Qiu X; Department of Medicine, Yale School of Medicine, New Haven, Connecticut., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Davidsohn MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Savignano H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Lakshminarayanan G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., McClure HM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Canniff J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Fortunato B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Li R; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Banwait MK; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Semaan K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Eid M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Long H; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Hung YP; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Piotrowska Z; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Hata AN; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3798-3811. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
